title: Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
abstract: BACKGROUND
  In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, dutasteride reduced the relative risk of prostate cancer (CaP) diagnosis over a 4-year period by 22.8%, but questions remain regarding the cost-effectiveness of widespread utilization. We evaluated the cost utility of chemoprevention using dutasteride in men at elevated risk for CaP.
  
  
  METHODS
  A Markov decision analysis model with probabilistic sensitivity analysis was designed to determine the lifetime prostate-health-related costs, beginning at age 50, for men treated with dutasteride compared with placebo who are at elevated risk for CaP. Model assumptions were based on data in REDUCE; surveillance, epidemiology, and end-results program; literature review of costs, utilities, and transition rates among various prostate cancer health states; and local institutional cost data.
  
  
  RESULTS
  Under the assumptions of the base case analysis, dutasteride chemoprevention is associated with a gain of 108 quality-adjusted life-years (QALYs) per 1,000 men and the quality-adjusted cost-effectiveness ratio for dutasteride compared with men not receiving chemoprevention was $140,240 per QALYs. At a cost of $626 per year, down from the current cost of $1,400, the model predicts a cost benefit from dutasteride with a willingness-to-pay threshold lower than $50 K. Assuming a 15% period prevalence renders, an incremental cost-effectiveness ratio of $576,630 per QALYs and a 30% period prevalence would yield a $98,059 per QALYs.
  
  
  CONCLUSIONS
  Dutasteride is unlikely to be cost effective when considering the impact on survival differences among treated versus untreated groups. However, chemoprevention may be cost effective in high-risk populations when taking into consideration adjustments for the impact on quality of life.
authors.affiliation: Department of Urology, The University of Texas San Antonio, TX, USA.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Svatek
authors.forename: Yair
authors.initials: Y
authors.lastname: Lotan
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D001378:Azasteroids / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D000068538:Dutasteride; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000191:economics* / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000097:blood / Q000191:economics* / Q000517:prevention & control*; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D017430:Prostate-Specific Antigen; D000068538:Dutasteride